Enzo Biochem (NYSE:ENZ) announces a
Comprehensive COVID-19 Program incorporating its molecular diagnostic
virus screening products, detection for immunity through IgG/IgM
serological ELISA products, detection of inflammation on its ELISA
platform, and a promising proprietary drug candidate (SK1-I).
Enzo is currently offering COVID-19 test kits
under the FDA’s Emergency Use Authorization (EUA) authority, which uses
its proprietary GENFLEX open diagnostic platform.
The new COVID-19 test features improved scale, sensitivity, and more relevant positive control materials.
https://seekingalpha.com/news/3563594-enzo-bio-up-19-premarket-on-launch-of-covidminus-19-blood-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.